The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | VAG regimen drives immune reprogramming and superior remission in older/unfit patients with AML
In this interview, Hong-Hu Zhu, MD, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China, discusses the potential of the VAG regimen, a novel treatment approach for older or unfit patients with acute myeloid leukemia (AML) that combines venetoclax, azacitidine, and granulocyte colony-stimulating factor (G-CSF) and was evaluated in a Phase II trial (ChiCTR2300078290). This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I’m very glad to have the opportunity to present our clinical trial and the mechanism of this new regimen named VAG regimen to treat newly diagnosed acute myeloid leukemia. In this study, we tried treat AML patients with VAG regimen, including three drugs, Azacitidine, venetoclax, and G-CSF. These three drugs treat as the first-line treatment of newly diagnosed AML patients...
I’m very glad to have the opportunity to present our clinical trial and the mechanism of this new regimen named VAG regimen to treat newly diagnosed acute myeloid leukemia. In this study, we tried treat AML patients with VAG regimen, including three drugs, Azacitidine, venetoclax, and G-CSF. These three drugs treat as the first-line treatment of newly diagnosed AML patients. This cycle includes five days of Azacitidine and 21 days of venetoclax and G-CSF for seven days. This regimen has achieved a very high remission rate, about 82%. This high efficacy versus standard of care of Venetoclax plus Azacitidine regimen. We were very curious to know why adding G-CSF has enhanced cytotoxicity to venetoclax-azacitidine. We found that this G-CSF can enhance the effect of the immune cells, including cytotoxic T-cells and NK-cells. This novel mechanism of the G-CSF to enhance human immunity effect to anti-leukemia effect. So our results have novel insight to enhance the anti-leukemia effect to treat elderly AML patients.
I think this new regimen will improve high remission rates in this population, and we want this high remission rate to transform into overall survival benefits. We have completed Phase II clinical trials and published our results in the Blood Cancer Journal. And now we are going to the clinical trial of the Phase III randomized clinical trial to compare VA treatment to VAG regimen. We await the promising results to confirm our results of the Phase II clinical trial. Thank you very much.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
